The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Giotrif afatinib | Boehringer Ingelheim International GmbH | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2013-09-25 | Order → |
| Imatinib medac imatinib Generic | Medac | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dermatofibrosarcoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic-Myeloproliferative Diseas | 🇪🇺 EU 2013-09-25 | Order → |
| Incresync alogliptin;pioglitazone | Takeda Pharma A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2013-09-19 | Order → |
| Tybost cobicistat | Gilead Sciences Ireland UC | HIV Infections | 🇪🇺 EU 2013-09-19 | Order → |
| Ultibro Breezhaler indacaterol;glycopyrronium bromide | Novartis Europharm Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2013-09-19 | Order → |
| Vipdomet alogliptin;metformin | Takeda Pharma A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2013-09-18 | Order → |
| Vipidia alogliptin benzoate | Takeda Pharma A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2013-09-18 | Order → |
| Xoterna Breezhaler indacaterol;glycopyrronium bromide | Novartis Europharm Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2013-09-18 | Order → |
| Lemtrada alemtuzumab Additional monitoring | Sanofi Belgium | Multiple Sclerosis | 🇪🇺 EU 2013-09-12 | Order → |
| Orphacol cholic acid Exceptional circumstancesAdditional monitoring | Theravia | Digestive System Diseases; Metabolism, Inborn Errors | 🇪🇺 EU 2013-09-12 | Order → |
| Inflectra infliximab Biosimilar | Pfizer Europe MA EEIG | Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid | 🇪🇺 EU 2013-09-10 | Order → |
| Remsima infliximab Biosimilar | Celltrion Healthcare Hungary Kft. | Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid | 🇪🇺 EU 2013-09-10 | Order → |
| Provenge autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-T) ATMPAdditional monitoring | Dendreon UK Ltd | Prostatic Neoplasms | 🇪🇺 EU 2013-09-06 | Order → |
| Procysbi mercaptamine | Chiesi Farmaceutici S.p.A | Cystinosis | 🇪🇺 EU 2013-09-05 | Order → |
| Aubagio teriflunomide | Sanofi Winthrop Industrie | Multiple Sclerosis | 🇪🇺 EU 2013-08-26 | Order → |
| Cholib fenofibrate;simvastatin | Viatris Healthcare Limited | Dyslipidemias | 🇪🇺 EU 2013-08-26 | Order → |
| Nexium Control esomeprazole | Haleon Ireland Dungarvan Limited | Gastroesophageal Reflux | 🇪🇺 EU 2013-08-26 | Order → |
| Stivarga regorafenib | Bayer Pharma AG | Colorectal Neoplasms | 🇪🇺 EU 2013-08-26 | Order → |
| Tafinlar dabrafenib | Novartis Europharm Limited | Melanoma | 🇪🇺 EU 2013-08-26 | Order → |
| Voncento human coagulation factor VIII / human von willebrand factor | CSL Behring GmbH | Hemophilia A; von Willebrand Diseases | 🇪🇺 EU 2013-08-12 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.